<DOC>
	<DOC>NCT00169039</DOC>
	<brief_summary>This study will examine the physical response to clozapine or chlorpromazine in people with schizophrenia that has not improved with treatment.</brief_summary>
	<brief_title>Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia</brief_title>
	<detailed_description>This is a longitudinal double-blind 12-week study of the clinical and biochemical response to clozapine or chlorpromazine in a group of treatment-refractory schizophrenic patients. The study has 4 phases: (1) A recruitment period; (2) a period of discontinuation of psychotropic medication; (3) a drug-washout period; and (4) a 12-week double-blind trial of clozapine or chlorpromazine.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Clozapine</mesh_term>
	<mesh_term>Chlorpromazine</mesh_term>
	<criteria>1960 years of age Diagnosis of schizophrenia BPRS score &gt; 50 Clinical Global Impressions rating &gt; 4 One of the following: BPRS items rated greater than or equal to 4, conceptual disorganization, suspiciousness, hallucinations, unusual thought content. At least 2 sixweek trials of different neuroleptics given at a dosage equivalent to at least 600 mg per day of chlorpromazine OR at least 1 eightweek trial of a neuroleptic given at a dosage equivalent to at least 800 mg per day of chlorpromazine. The patient (or the patient's authorized legal representative) must understand the nature of the study and sign the informed consent. History of substance dependence within the past 2 months Major medical problems precluding the use of clozapine Pregnancy or lactation A serious suicide/homicide risk</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Clozapine</keyword>
	<keyword>Chlorpromazine</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Biochemistry</keyword>
</DOC>